Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards

Abstract

PurposeTo develop expert consensus on a suite of reporting standards for HRQL outcomes of RCTs.MethodsA Task Force of The International Society of Quality of Life Research (ISOQOL) undertook a systematic review of the literature to identify candidate reporting standards for HRQL in RCTs. Subsequently, a web-based survey was circulated to the ISOQOL membership. Respondents were asked to rate candidate standards on a 4-point Likert scale based on their perceived value in reporting studies in which HRQL was a study outcome (primary or secondary). Results were synthesized into draft reporting guidelines, which were further reviewed by the membership to inform the final guidance.ResultsForty-six existing candidate standards for reporting HRQL results in RCTs were synthesized to produce a 40 item survey that was completed electronically by 161 respondents. The majority of respondents rated all 40 items to be either ‘essential’ or ‘desirable’ when HRQL was a primary RCT outcome. Ratings changed when HRQL was a secondary study outcome. Feedback on the survey findings resulted in the Task Force generalizing the guidance to include patient-reported outcomes (PROs). The final guidance, which recommends standards for use in reporting PROs generally, and more specifically, for PROs identified as primary study outcomes, was approved by the ISOQOL Board of Directors.ConclusionsISOQOL has developed a suite of recommended standards for reporting PRO results of RCTs. Improved reporting of PROs will enable accurate interpretation of evidence to inform patient choice, aid clinical decision making, and inform health policy.

Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial

“…Any bias arising from missing data should be attenuated by similar levels of missing data across randomized groups. Our sensitivity analyses indicate that our findings are robust to missing data, and this greatly strengthens our interpretation 29, 30…”

Preliminary evidence on the uptake, use and benefits of the CONSORT-PRO extension

“…Of the 26 RCTs, the majority were oncology trials (n=10, 39%), fibromyalgia (n=3, 11%), haematology (n=2, 8%), genetic counselling (n=2, 8%) and weight management (n=2, 8%). 44/214 citing articles (including 3 RCTs) had a co-author who was involved in the development of CONSORT-PRO [12,9] or its predecessor, the ISOQOL PRO reporting standards [17].…”

Inclusion of patient-reported outcome measures in registered clinical trials: Evidence from ClinicalTrials.gov (2007–2013)

“…This discrepancy can be explained in that not all industry-sponsored trials are FDA- [13]. The International Society for Quality of Life Research has developed reporting standards for PROs in randomized controlled trials [28]. The use of PROMs continues to increase.…”